ライフサイエンスコーパス: recipient

1 on to occur later, when and if needed by the recipient.

2 and the potential to unfairly advantage the recipient.

3 ing cause of graft loss in kidney transplant recipients.

4 alidated for the UK population of transplant recipients.

5 elial carcinogenesis among kidney transplant recipients.

6 ble of inducing AML in serially transplanted recipients.

7 arding the optimal treatment approach in THV recipients.

8 uppressive therapy in solid organ transplant recipients.

9 of pregnancy and mortality of red blood cell recipients.

10 5%, 19%, and 30%, respectively, for Medicaid recipients.

11 adverse outcomes in stable kidney transplant recipients.

12 sociation with outcomes in kidney transplant recipients.

13 remalignant condition poorly described in KT recipients.

14 red cell incompatibility between donors and recipients.

15 d lymphomas that develop in organ transplant recipients.

16 chronic kidney disease and kidney transplant recipients.

17 ntibody-mediated damage in highly sensitized recipients.

18 (10/249) in donors and 18% (93/517) in organ recipients.

19 cells were able to transfer disease to naive recipients.

20 (non-HLAabs) were screened in 29 transplant recipients.

21 ses of morbidity and mortality in transplant recipients.

22 with 0% (n=0/25) to 35% (n=8/23) of control recipients.

23 ther, whereas group 3 was similar to placebo recipients.

24 ing 70% to 80% to improve HLA matching in CP recipients.

25 on strategies are warranted for kidney graft recipients.

26 as documented in 117 (39%) of 300 transplant recipients.

27 waitlist including KDPI 0% to 85% transplant recipients.

28 sulin sensitivity when administered to obese recipients.

29 sts, and antithymocyte globulin in high-risk recipients.

30 d patients and particularly organ transplant recipients.

31 ars) and older (25-34 years) registrants and recipients.

32 tcomes in 18- to 24-year-old registrants and recipients.

33 jection in HIV-to-HIV solid organ transplant recipients.

34 kidney outcomes in stable kidney transplant recipients.

35 ansplant, a total of 694 observations in HCT recipients.

36 tribute to allograft damage among transplant recipients.

37 llogeneic hematopoietic stem cell transplant recipients.

38 etransplant sensitization on lung transplant recipients.

39 330 pairs) and basiliximab-rATG (9378 pairs) recipients.

40 y among male recipients but not among female recipients.

41 f urologic malignancies in kidney transplant recipients.

42 ld lead to improved outcomes for solid organ recipients.

43 have suboptimal immunogenicity in transplant recipients.

44 the posttransplant evaluation for 70 kidney recipients.

45 er transplantation (LT) compared to other LT recipients.

46 ibody responses were detected in all vaccine recipients.

47 810.85, P < 0.001) and 14% per year for LDKT recipients (0.790.860.93, P < 0.001).

48 emained, but decreased 14% per year for DDKT recipients (0.830.860.89, P < 0.001) and 9% per year for

49 .860.89, P < 0.001) and 9% per year for LDKT recipients (0.850.910.98, P < 0.001).

50 and PXR) were analyzed in kidney transplant recipients (1995-2005, Leiden cohort, n = 153) treated w

51 Of the 665 LT recipients, 457 (68.7%) had AFP-producing tumors, and 20

52 cal study including healthy heart transplant recipients 6 months to 25 years of age presenting for ro

53 s (n = 9850) that included kidney transplant recipients (6 trials), patients who had stage 3 to 5 CKD

54 certained outcomes in the corresponding 2435 recipients, 756 of whom experienced delayed graft functi

55 Fifty-three recipients (8.9%) had dnDSA at 1 year.

56 93% (n=139/149) to 100% (n=48/48) of vaccine recipients achieved protective hSBA titres equal to or g

57 cipients, PCNSL incidence was lower in liver recipients (adjusted incidence rate ratio [aIRR] = 0.52)

58 nt rVSV viremia was noted in all the vaccine recipients after dose 1.

59 f immunosuppressive therapy and inversely to recipient age.

60 Kidney transplants performed for pediatric recipients (age, <18 years) in the United Kingdom from 2

61 Heart transplantation recipients aged 2 to 40 years, transplanted between Octo

62 adolescent deceased donor kidney transplant recipients aged 21 years or younger using Australia and

63 cipients, and higher in other/multiple organ recipients (aIRR = 2.45).

64 pproach targets donor organs rather than the recipient and is intended to be directly translatable to

65 mpact of aging on both the allograft and the recipient and its effect on the immune response to organ

66 f TMAT, which occurred in a liver transplant recipient and resulted in death from bleeding complicati

67 nd 24 months after vaccination in 1006 PCV13 recipients and 1005 controls with 3 age-stratified study

68 ause all 800 (n = 5) and 1200 islets (n = 5) recipients and 40% of the 400 islets (n = 5) recipients

69 was 52 years (range, 18 to 74 years) for HCT recipients and 55 years (range, 19 to 73 years) for cont

70 were sequestrated in the circulation of the recipients and failed to reach the endocrine cells of gr

71 verse event, as did all three (100%) placebo recipients and one (33%) of three Nexvax2 150 mug recipi

72 Transplant recipients and other immunocompromised hosts are at part

73 The study cohort included 2609 HCT recipients and their donor pairs: 483 with proven/probab

74 ]) and survival in all lung transplant (LTx) recipients and those with either persistent or no DM.

75 eic hematopoietic stem cell transplant (HCT) recipients and Triplex in healthy adults motivated the i

76 MELD score (within 3 points of the regional recipient), and 209 (72%) were eventually transplanted i

77 The top 15 donor, recipient, and transplant factors influencing the outcom

78 topoietic stem cells in secondary transplant recipients, and enhanced survival of mice after disconti

79 [aIRR] = 0.52), similar in heart and/or lung recipients, and higher in other/multiple organ recipient

80 , immunocompetent individuals, in transplant recipients, and in PTLD patients.

81 ted in approximately 20% of renal transplant recipients, and it may rarely cause JCPyV-associated nep

82 d ED use rates among kidney transplant (KTx) recipients, and the factors associated with higher ED us

83 paired recipient, the naming of alternative recipients, and the potential to unfairly advantage the

84 Solid organ transplant recipients are at increased risk for developing malignan

85 Solid organ transplant (SOT) recipients are at risk of nocardiosis, a rare opportunis

86 Approximately 200 000 kidney transplant recipients are living in the United States; they are at

87 Pediatric liver transplant recipients arguably have the most to gain and the most t

88 0 patients in the cohort of renal transplant recipients at our institution, 15 subjects were included

89 recipients and 40% of the 400 islets (n = 5) recipients became normoglycemic within 8 days.

90 study of 1996 adult first kidney transplant recipients between 1991 and 2010 in the Republic of Irel

91 ected from 1799 consecutive liver transplant recipients between January 1, 2002, and December 31, 201

92 sease in hematopoietic cell transplant (HCT) recipients but does not lead to resolution of viremia wi

93 ith increased all-cause mortality among male recipients but not among female recipients.

94 BV) recurrence in liver transplantation (LT) recipients, but HBIG is costly and inconvenient to admin

95 and serum hsTnI levels increased in placebo recipients, but they remained largely unchanged in those

96 spital transfusion were frequency matched to recipients by mechanism of injury, prehospital shock, se

97 Recipient CD154+TcM induced by stimulation with donor ce

98 replication of the infectious agents in the recipient cell.

99 totoxicity and anti-migration) on drug-naive recipient cells (Recipient cells).

100 nd microRNA (miR) that can be transferred to recipient cells and regulate cellular processes in an au

101 ti-migration) on drug-naive recipient cells (Recipient cells).

102 and seeds aggregation of the protein in the recipient cells.

103 d cytotoxicity of PTX-containing exosomes on Recipient cells.

104 but might continue to exert their effects on recipient cells.

105 uency, patterns of acceptance, and donor and recipient characteristics associated with deceased donor

106 nor grafts and successful treatment of older recipients, chronic graft-versus-host disease (cGVHD) ha

107 tissues release donor-specific exosomes into recipient circulation and that the quantitation and prof

108 availability on temporal variability of the recipient community.

109 cost-effectiveness of OAT for all treatment recipients compared with the observed standard of care f

110 o virus negativity was 5.5 days in pocapavir recipients, compared with 13 days in placebo recipients

111 from wild-type HFD donor mice into HFD Bnull recipients completely restored the effect of HFD to indu

112 ment of uncertainty, the extent of donor and recipient consent, the scope of the obligation that the

113 cluding exchange of a disc of full-thickness recipient cornea (up to the DSAEK stromal surface),7.0 m

114 s: Immediate access to OAT for all treatment recipients costs less (by $78 257), with patients accumu

115 rs associated with higher mortality included recipient cytomegalovirus seropositivity (HR 1.40, 95% C

116 d national Scientific Registry of Transplant Recipients data (1987-2015) with records from a nationwi

117 Using Scientific Registry of Transplant Recipients data from June 2013 to June 2015, we identifi

118 We used Scientific Registry of Transplant Recipients data to compare patients listed with HCC who

119 the contribution of acquired MHC-class I on recipient DCs during the life span of a skin graft.

120 We observed that MHC-class I acquisition by recipient DCs occurs for at least 1 month following tran

121 Fecal microbiota analysis of 3 successful FT recipients demonstrated increased diversity.

122 neonatal IL-2Rbeta(-/-) mice, the secondary recipients developed autoimmunity.

123 ch patients (seropositive donor/seronegative recipient) developed a primary infection, one of whom de

124 s showing acute rejection, samples from FCRx recipients did not show upregulation of T cell- and B ce

125 During a median follow-up of 6.8 years, 256 recipients died, 35 (13.7%) from recurrent cancer and 27

126 across the genome to discriminate donor and recipient DNA molecules.

127 by multivariate Cox regression adjusted for recipient, donor, and transplant factors.

128 eGFR and balanced out the negative effect of recipient/donor characteristics.

129 1508176 high-dose and 1877327 standard-dose recipients during 2013-2014.

130 n 318 serum samples from 69 liver transplant recipients enrolled in the Immune Tolerance Network immu

131 history from 977 prevalent kidney transplant recipients enrolled in the Malnutrition-Inflammation in

132 Young adult heart transplantation (HTx) recipients experience high mortality risk attributed to

133 correlated to clinical outcome parameters of recipient eyes 12 months after surgery and 3 months afte

134 initiate inflammation in the HEL-expressing recipient eyes.

135 ved to predict graft failure using donor and recipient factors, based on local data sets, will be mor

136 As a consequence, HVEM-deficient recipients failed to afford protection against respirato

137 Transfer of such blastocysts to recipient females doubles mean litter size to about nine

138 he three-dose study, six (55%) of 11 placebo recipients, five (56%) of nine who received Nexvax2 60 m

139 There were 658 recipients followed up for a median of 5.5 years between

140 There were 367 recipients followed up for a median of 9.7 years between

141 ited States where competition is highest and recipients frequently attain a Model for End-Stage Liver

142 a registry used a cohort of renal transplant recipients from the United States Renal Data System (USR

143 Cognitive functioning in autologous HCT recipients generally was spared.

144 Transplant recipients had elevated incidence for PCNSL compared wit

145 Compared with non-LSG patients, post-LSG recipients had lower rates of DGF (5% vs 20%) and renal

146 Myeloablative HCT recipients had significantly lower ( P < .001) post-HCT

147 of graft failure in young kidney transplant recipients has been found to increase during adolescence

148 We conclude that older KT recipients have a high risk of post-KT dementia and AD,

149 l outcomes of MGUS in kidney transplant (KT) recipients have been previously reported in few studies

150 Low-toxicity myeloablative conditioning recipients have better B-lymphocyte/myeloid chimerism an

151 stochastic viral replication dynamics within recipient hosts.

152 phocyte reactions revealed modulation of the recipient immune response after AD-MSC treatment.

153 ecords of Medicare-insured kidney transplant recipients in 2000 to 2011 to determine clinical and eco

154 l rate, has become widely adopted in elderly recipients in an old-to-old allocation system.

155 ients and one (33%) of three Nexvax2 150 mug recipients in the biopsy cohort.

156 nor-derived Tregs from an individual primary recipient into neonatal IL-2Rbeta(-/-) mice, the seconda

157 s affects the antibody repertoire of vaccine recipients is inadequate.

158 imal vaccination schedule in lung transplant recipients is unknown.

159 gnificantly (p < 0.05) improved function and recipient Lewis rat survival compared to UW solution alo

160 ocytes or the regenerative impairment of the recipient livers.

161 in ABO-incompatible (ABOi) renal transplant recipients managed solely with antibody removal and conv

162 sk factors for CMV infection in pediatric LT recipients managed with ganciclovir-based preemptive the

163 Donor-recipient match quality was estimated from the donor ris

164 ontrol groups without prior angiogram, 72 LT recipients matched for cardiovascular risk factors (cont

165 Even without specific donor/recipient matching criteria, the outcomes of LT with don

166 Longer LOS among nonfrail recipients may be a marker of increased mortality risk.

167 the altered response of B cells in tolerant recipients may contribute to long-term stable graft acce

168 mon occurrence of GI disorders in transplant recipients may delay diagnosis of GITB.

169 We now report that the recovery of both recipient MDSCs (P < .01) and MDCs (P < .01) is signific

170 s in a cohort of 10 stable kidney transplant recipients (median of 4.3 years posttransplantation) wit

171 d mice and transplanted into naive mice, the recipient mice (UV-chimeric) had reduced accumulation of

172 environment, and the deletion of moesin from recipient mice supported the rapid expansion of adoptive

173 tigens efficiently break immune tolerance of recipient mice, capturing several key features of PBC, i

174 e distal colon of 3- to 4-week-old wild-type recipient mice.

175 function, fibrosis, and hypertrophy in naive recipient mice.

176 id cells with damaged epithelia and with the recipient microbiome, the impact of the alarmin interleu

177 iver transplant registrants (n = 13 979) and recipients (n = 8718) ages 0 to 34 years between 2002 an

178 nosuppressive strategies for lung transplant recipients need to be tailored based on the unique immun

179 LT recipients needing full assistance (KPS 10%-40%) vs bein

180 rence, donor serum sodium, and pretransplant recipient neutrophil-lymphocyte ratio.

181 e a case of probable donor-derived KS in the recipient of a liver-kidney transplant.

182 Barbara McClintock, geneticist and recipient of the 1983 Nobel Prize in Physiology or Medic

183 associated with reduced risk of DGF in both recipients of AKI donor kidneys (adjusted relative risk,

184 ll four dengue virus serotypes (DENV-1-4) in recipients of all ages.

185 older individuals are likely to be important recipients of anti-GRP78 therapy.

186 RAG1(-/-) recipients of BALB/c cardiac allografts were passively t

187 Recipients of DCD kidneys with DGF experienced a higher

188 Compared with recipients of defibrillators, the excess mortality in pa

189 g organ donors and transplant outcomes among recipients of donors with positive ZIKV testing.

190 usted survival was significantly worse among recipients of EG compared to recipients of younger graft

191 We studied 1039645 recipients of high-dose and 1683264 recipients of standa

192 serious adverse events were identified among recipients of HRV, but none were considered related to r

193 Among recipients of male donors, females of all ages had signi

194 or highest versus lowest YKL-40 tertile) and recipients of non-AKI donor kidneys (adjusted relative r

195 The outcomes of recipients of organs from deceased donors with ITP recor

196 Transplant outcome was similar in recipients of organs from donors with and without IRB.

197 We suggest that in contexts where recipients of selfish acts are capable of resistance, th

198 We analyzed recipients of simultaneous pancreas and kidney and pancr

199 number of patients with similar outcomes in recipients of single and dual ECD kidneys.

200 1039645 recipients of high-dose and 1683264 recipients of standard-dose vaccines during 2012-2013, a

201 ultivariable models and were strongest among recipients of T-cell-replete allografts.

202 emained at 3 IU or less per deciliter in the recipients of the low or intermediate dose.

203 tly worse among recipients of EG compared to recipients of younger grafts (P < .0001).

204 for KDPI greater than 85% of transplants in recipients older than 60 years, preKT had a reduced mort

205 isk of skin cancer in solid organ transplant recipients (OTRs), no study has estimated the posttransp

206 well characterized in white organ transplant recipients (OTRs); however, most patients on the waiting

207 pecific plasmablast responses in HIV-vaccine recipients over a period of 42 d and performed a head-to

208 recipients, compared with 13 days in placebo recipients (P < .0001).

209 We identified 4319 HCT donor-recipient pairs (8638 subjects) who received an allogene

210 etrospectively studied 1199 paediatric donor-recipient pairs with allele-level HLA matching who recei

211 solates from the donor and the corresponding recipient (patient 1) were closely related and formed a

212 Compared to kidney recipients, PCNSL incidence was lower in liver recipient

213 This novel function of recipient PD-L1 may result from the high degree of T-cel

214 inges distributed per PWID per year; <20 OST recipients per PWID per year).

215 thelial cells were reliably characterized in recipient plasma over follow-up periods of up to 5 years

216 Three lung transplant recipients presented with invasive M. hominis infections

217 cal compatibility of a donor and an intended recipient prior to a blood transfusion.

218 te the dedicated maturation of specific Fe/S recipient proteins.

219 initial synthesis and subsequent binding to recipient proteins.

220 d by the large differences between donor and recipient RBC survival times.

221 United States, 5% of adult liver transplant recipients receive a graft donation after circulatory de

222 ion of pre-detection cryptic transmission in recipient regions.

223 pertoire was substantially narrowed, yet the recipients remained autoimmune-free.

224 idneys have less favorable donor, graft, and recipient risk factors than NKAS kidneys, short-term gra

225 ted significantly greater (13) C transfer to recipient roots in two of four Douglas-fir families, rep

226 Only recipient's age and elevated international normalized ra

227 On multivariate analysis, recipient's age and elevated pre-LT international normal

228 elates with tacrolimus trough levels and the recipient's individualized alloimmune risk determined by

229 practices, optimizing HIV-infected donor and recipient selection, managing donor-derived transmission

230 Communication support program recipients' self-efficacy in knowing what questions to a

231 n 5-week follow-up biopsies, while another 2 recipients showed a substantial decrease in C4d scores.

232 Conclusion Myeloablative allogeneic HCT recipients showed significant cognitive decline compared

233 After adjustment for recipient sociodemographics, donor, and transplant chara

234 Solid organ transplant recipients (SOTR) with a pretransplant malignancy (PTM)

235 donor (after prophage induction) and in the recipient strain (for infection).

236 for phage replication, both in the donor and recipient strain.

237 ity RBCs is not without consequence, because recipients subsequently develop Ag-specific tolerance.

238 ganic compounds for fresh water organisms in recipient surface waters.

239 N + all), and an additional source extending recipient survival time if no death was found in OPTN +

240 eaction between antigen-presenting cells and recipient T cells.

241 ganization has to the kidney exchange paired recipient, the naming of alternative recipients, and the

242 Among placebo recipients, the respective incidence of PCR-CI and SDI w

243 Among RIV4 recipients, the RT-PCR-confirmed influenza attack rate w

244 of adverse events among vaccine and placebo recipients throughout the study.

245 emained, but decreased 19% per year for DDKT recipients (time varying coefficient 0.780.810.85, P < 0

246 cells leads to the upregulation of PD-L1 by recipient tissues and donor CD8+ T cells.

247 s peripheral blood T cells and expand in the recipient to eliminate the targeted tumor.

248 sequence of viruses from vaccine and placebo recipients to the sequence of the vaccine itself, a tech

249 Median follow-up time was 6.7 years per recipient; total follow-up time, 69590 person-years.

250 Genomic data suggest donor-to-recipient transmission of M. hominis.

251 We studied a validation cohort of 98 heart recipients transplanted in Edmonton, AB, Canada, includi

252 Recipients treated with tacrolimus who developed HLA-DR/

253 Five of 8 C4d-positive recipients turned C4d-negative in 5-week follow-up biops

254 Lymphocytes from 20 recipients undergoing alemtuzumab-induced depletion and

255 retrospective study of US kidney transplant recipients undergoing PCI, DES was associated with bette

256 fference in LOS for Medicaid vs non-Medicaid recipients varied significantly by state.

257 The unadjusted rates for dementia in ADT recipients versus nonrecipients were 38.5 and 32.9, resp

258 viral genome sequences from blood donors and recipients, we assess the dynamics of dengue virus serot

259 lind study of 162 HIV-negative RV144 vaccine recipients, we evaluated 2 additional boosts, given 6-8

260 e with commercial health insurance, Medicaid recipients were 234% more likely to not receive any glau

261 vered iTreg cells from the lungs of CD8(-/-) recipients were capable of IL-17 production and expresse

262 Recipients were cross-referenced with the National Cance

263 Twenty-four (23.3%) of 103 recipients were diagnosed with PAT (including grade 1).

264 a from the Scientific Registry of Transplant Recipients were linked to IMS pharmacy fills (January 1,

265 omes in HLA-phenotypically matched unrelated recipients were low, relative to the large difference in

266 ouble-blind, placebo-controlled trial, 96 HT recipients were randomized to undergo ramipril or placeb

267 records of the donor and infected transplant recipients were reviewed for clinical characteristics.

268 The SPK and LDK recipients were similar in age (41.2 +/- 6.9 years vs 40

269 nd demographic characteristics of donors and recipients, were selected to assess their independent as

270 ving corticosteroids in pediatric transplant recipients which reported growth as change in height or

271 Despite transplant centers accepting recipients who are older with more comorbidities in rece

272 er, 79 kidney, and 5 liver-kidney transplant recipients who completed treatment for an episode of CMV

273 ection and all-cause mortality at 3 years in recipients who have experienced DGF were 0.98 (95% CI, 0

274 positive living donor HLAi kidney transplant recipients who received their transplant between Jan 1,

275 All the patients in the cohort were Medicare recipients who were at least 65 years of age.

276 Medicaid recipients who were the oldest ICU survivors (> 82 yr),

277 dentifying information about the prospective recipient (whose life was saved by the donation) increas

278 Kidney transplant recipients with a pretransplant cancer had a similar ove

279 dated in an independent cohort of 202 kidney recipients with ABMR (C-statistic=0.79).

280 Twelve renal transplant recipients with aHUS-related end-stage renal disease rec

281 The cohort included 1671 recipients with and 102 961 without pretransplant skin m

282 Allograft transplantation into sensitized recipients with antidonor antibodies results in accelera

283 Organ transplant recipients with CF should initiate CRC screening at age

284 We identified 45 kidney transplant recipients with dnDSA detected between January 2014 and

285 (in hospital only) HBIG in liver transplant recipients with HBV DNA less than 100 IU/mL pre-LT.

286 We retrospectively reviewed HCT recipients with HCoV detected in nasal samples by polyme

287 Eighty-seven LT recipients with history of pre-LT angiogram (December 20

288 model is significantly improved by treating recipients with inhaled 50% oxygen, in conjunction with

289 iency virus/HCV coinfected kidney transplant recipients with ledipasvir-sofosbuvir at our 2 centers.

290 19 450 deceased donor kidney transplantation recipients with Medicare as primary payer from 2000 to 2

291 osttransplant malignancy in kidney allograft recipients with negative pretransplant HBc, HCV, EBV, or

292 Recipients with preformed DSA demonstrated elevated risk

293 ransplant de novo malignancies exist between recipients with PTM and those without PTM.

294 Similarly, recipients with PTM were 3 times more likely to die of c

295 Among renal transplant recipients with STEMI, the use of reperfusion increased

296 As a result, recipients with tBKVN had borderline increased incidence

297 Kidney transplant recipients with urinary angiogenin amounts in the highes

298 rs (control group I), and 119 consecutive LT recipients without any CV risk factors (control group II

299 CI, 0.36-7.93), respectively, compared with recipients without DGF.

300 imilar overall patient and graft survival as recipients without such cancer.